54536-22-0

Upstream product

• 26053-96-3 4-acetoxy-4'-methoxyazobenzene 
• 123-30-8 4-amino-phenol 
• 865-50-9 iodomethane-d3 
• 103-90-2 4-acetaminophenol 
• 15199-43-6 d6-dimethyl sulfate 
• 108-24-7 acetic anhydride 

Downstream Products

• 922730-95-8 2-nitro-4-trideuteriomethoxyaniline 
• 180626-23-7 4-([D₃]methoxy)aniline 
• 922730-96-9 d3-2-nitro-4-methoxy acetanilide 

Relevant academic research and scientific papers

PHARMACEUTICAL COMPOUNDS AND THERAPEUTIC METHODS

The invention provides compounds of formula (16) and (17); and salts thereof, as well as compositions comprising such compounds and salts, complexes comprising such compounds and salts, and methods for treating cancer, inhibiting BMI1 expression, or treating Huntington's disease using such compounds, salts, and complexes. The compounds, salts, and complexes have potency, permeability, and oral bioavailability that make them particularly useful, for example, for the treatment of glioblastoma.

Design and Synthesis of Novel Deuterated Ligands Functionally Selective for the γ-Aminobutyric Acid Type A Receptor (GABAAR) α6 Subtype with Improved Metabolic Stability and Enhanced Bioavailability

Recent reports indicate that α6β2/3γ2 GABAAR selective ligands may be important for the treatment of trigeminal activation-related pain and neuropsychiatric disorders with sensori-motor gating deficits. Based on 3 functionally α6β2/3γ2 GABAAR selective pyrazoloquinolinones, 42 novel analogs were synthesized, and their in vitro metabolic stability and cytotoxicity as well as their in vivo pharmacokinetics, basic behavioral pharmacology, and effects on locomotion were investigated. Incorporation of deuterium into the methoxy substituents of the ligands increased their duration of action via improved metabolic stability and bioavailability, while their selectivity for the GABAAR α6 subtype was retained. 8b was identified as the lead compound with a substantially improved pharmacokinetic profile. The ligands allosterically modulated diazepam insensitive α6β2/3γ2 GABAARs and were functionally silent at diazepam sensitive α1β2/3γ2 GABAARs, thus no sedation was detected. In addition, these analogs were not cytotoxic, which render them interesting candidates for treatment of CNS disorders mediated by GABAAR α6β2/3γ2 subtypes.

LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS ANS THEIR METHODS OF USE

Provided herein are novel pyrazoloquinolinone compounds and method of using such compounds to treat disorders such as neuropsychiatric disorders with sensorimotor gating deficits, such as schizophrenia, tic disorders, attention deficit hyperactivity disorder, obsessive compulsive disorder, panic disorder, Huntington's disease and nocturnal enuresis;depression; temporomandibular myofascial pain; disorders of trigeminal nerve, such as trigeminal neuralgia and trigeminal neuropathy; migraine; and tinnitus.

Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties

Chemical syntheses and medical uses of novel inhibitors of the gastric H+, K+-ATPase for the treatment and/or management of duodenal ulcers, heartburn, acid reflux, other conditions mediated by gastric acid secretion and/or psoriasis are described.

ISOTOPICALLY SUBSTITUTED PROTON PUMP INHIBITORS

The invention relates to benzimidazoles of Formula (1) and to pharmaceutical compositions comprising these compounds, further to intermediates of Formula (2 and 3).

The Synthesis of Specifically and Selectively Deuteriated 4,4'-Bisalkoxyazoxybenzene Derivatives

In connection with deuterium n.m.r. studies of molecular motion in liquid crystals we have developed a number of methods for the synthesis of selectively deuteriated 4,4'-bisalkoxyazoxybenzenes.This paper is concerned with (i) the labelling of specific methylene segments of the alkoxy-chains, (ii) the labelling of the aromatic nucleus, and (iii) the selective enrichment of the deuterium content of one alkoxy-chain relative to the other.Our studies of the n.m.r. spectra of these liquid crystals have shown that there is not (as has sometimes been supposed) a monotonic decrease in C-D quadrupole splitting in passing from the oxygen to the CD3 end of the alkoxy-chain.In -PAA (p-azoxyanisole) we have also shown that the smaller splitting is associated with the CD3O group nearest to the NO end of azoxy-group.Whereas the photorearrangement of azoxy-compounds is normally regiospecific, the photorearrangement of PAA selectively deuteriated in one methoxy-group is unusual in that it leads to isotopically scrambled products.